Vildagliptin API: DPP-4 Inhibitor for Type 2 Diabetes
Vildagliptin is an oral antidiabetic medicine used for type 2 diabetes management. This article looks at the API profile and its use in combination tablets.
Overview of Vildagliptin API
Vildagliptin is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor used for the management of type 2 diabetes mellitus, often in combination with metformin or other antidiabetic agents. It helps improve glycaemic control without significant risk of hypoglycaemia when used appropriately.
Indications
- Monotherapy in type 2 diabetes when diet and exercise alone are insufficient
- Combination therapy with metformin, sulfonylureas, or insulin as per local labelling
API and Formulation Considerations
Vildagliptin API is typically formulated into film‑coated tablets, either alone or as fixed‑dose combinations. Quality control focuses on assay, related substances, residual solvents, and appropriate stability data to ensure shelf‑life performance.
Share this article:
About Vubrix Pharma Team
Our team of pharmacists and medical writers share accurate, easy-to-understand medicine information for healthcare professionals and patients.
Related Articles
Aripiprazole API: Uses, Pharmacology, and Quality Specifications
Learn about Aripiprazole active pharmaceutical ingredient (API) – indications, mechanism of action, typical finished dosage forms, and key quality parameters for reliable sourcing.
Fluconazole API: Antifungal Uses, Dosage Forms, and Quality Parameters
Discover key information about Fluconazole active pharmaceutical ingredient (API), including indications, mechanism of action, typical dosage forms, and quality expectations.
Aceclofenac API: NSAID Uses, Formulations, and Safety Highlights
Technical and clinical overview of Aceclofenac API, a widely used NSAID for pain and inflammation, including its mechanism, indications, and formulation considerations.